- Home
- KPRX vs XTIA Comparison
KPRX vs XTIA Comparison
Compare KPRX & XTIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- XTIA
- Stock Information
- Founded
- KPRX 1998
- XTIA 1999
- Country
- KPRX United States
- XTIA United States
- Employees
- KPRX N/A
- XTIA 50
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XTIA
- Sector
- KPRX Health Care
- XTIA
- Exchange
- KPRX Nasdaq
- XTIA NYSE
- Market Cap
- KPRX 10.0M
- XTIA 19.7M
- IPO Year
- KPRX N/A
- XTIA N/A
- Fundamental
- Price
- KPRX $3.91
- XTIA $5.98
- Analyst Decision
- KPRX Strong Buy
- XTIA
- Analyst Count
- KPRX 1
- XTIA 0
- Target Price
- KPRX $10.00
- XTIA N/A
- AVG Volume (30 Days)
- KPRX 54.6K
- XTIA 2.0M
- Earning Date
- KPRX 11-08-2024
- XTIA 02-26-2025
- Dividend Yield
- KPRX N/A
- XTIA N/A
- EPS Growth
- KPRX N/A
- XTIA N/A
- EPS
- KPRX 1.69
- XTIA N/A
- Revenue
- KPRX $16,020,000.00
- XTIA $2,169,000.00
- Revenue This Year
- KPRX N/A
- XTIA N/A
- Revenue Next Year
- KPRX N/A
- XTIA N/A
- P/E Ratio
- KPRX $2.31
- XTIA N/A
- Revenue Growth
- KPRX N/A
- XTIA N/A
- 52 Week Low
- KPRX $3.00
- XTIA $3.85
- 52 Week High
- KPRX $8.98
- XTIA $2,000.00
- Technical
- Relative Strength Index (RSI)
- KPRX 60.98
- XTIA 41.12
- Support Level
- KPRX $3.10
- XTIA $5.36
- Resistance Level
- KPRX $4.00
- XTIA $6.86
- Average True Range (ATR)
- KPRX 0.25
- XTIA 4.75
- MACD
- KPRX 0.02
- XTIA -0.73
- Stochastic Oscillator
- KPRX 90.00
- XTIA 3.79
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About XTIA XTI AEROSPACE
XTI Aerospace Inc is a development-stage aircraft manufacturer. XTI is developing a vertical takeoff and landing (VTOL) aircraft, the TriFan 600, which is a design-stage six-passenger aircraft that it anticipates will provide point-to-point air travel over distances of up to 700 miles while significantly reducing carbon emissions per mile compared to today's gasoline-powered jet aircraft and helicopters. The TriFan 600 is expected to have a wide usage ranging from private and commercial aviation services for businesses and high-net-worth individuals to emergency medical services (EMS). The Company's operations are located primarily in the United States, Germany, and the United Kingdom.